Dr Reddy’s completes sale of US rights for 2 neurology products

Drug major Dr Reddy’s Laboratories on July 20 said it has completed sale of its US and select territory rights for two neurology products to Upsher-Smith Laboratories. The company has closed the transaction with Upsher-Smith Laboratories LLC, “pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended,” Dr Reddy’s Laboratories said in a filing to BSE. Under the agreement, Dr Reddy’s sold its US and select territory rights for Zembrace Symtouch (sumatriptan injection)…

Read More

Lupin gains on exclusive rights to sell Aptissen products in Canada

Shares of Lupin rose 1 percent intraday Thursday as company entered into definitive distribution agreement with Aptissen S.A. Lupin and Aptissen S.A. entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada, company said in BSE filing. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already…

Read More